secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000950170-25-083441
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA refuses to file Axsome's NDA for AXS-14 (esreboxetine) for fibromyalgia; new trial required
--------------------------------------------------------------------------------

- FDA issued RTF letter; second placebo-controlled trial deemed inadequate due to 8-week endpoint and flexible-dose design.
- First trial (12-week, fixed-dose) accepted as adequate; both trials met primary endpoints with no efficacy concerns raised.
- Axsome will conduct a new fixed-dose, 12-week trial; initiation expected in Q4 2025.
- Delay extends approval timeline for potential treatment of ~17 million U.S. fibromyalgia patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025083441/0000950170-25-083441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025083441/axsm-20250609.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer